[go: up one dir, main page]

WO1998009623A3 - Use of cholinergic drugs - Google Patents

Use of cholinergic drugs Download PDF

Info

Publication number
WO1998009623A3
WO1998009623A3 PCT/GB1997/002349 GB9702349W WO9809623A3 WO 1998009623 A3 WO1998009623 A3 WO 1998009623A3 GB 9702349 W GB9702349 W GB 9702349W WO 9809623 A3 WO9809623 A3 WO 9809623A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholinergic drugs
conditions
acetyl choline
cholinergic
unassociated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1997/002349
Other languages
French (fr)
Other versions
WO1998009623A2 (en
Inventor
Birgitta Brunes
Christian Brunes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Priority to AU40270/97A priority Critical patent/AU4027097A/en
Publication of WO1998009623A2 publication Critical patent/WO1998009623A2/en
Publication of WO1998009623A3 publication Critical patent/WO1998009623A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Medicament for use in a syndrome shown in multiple sclerosis, depression and other conditions, and also in tinnitus and sterile prostatitis unassociated with such conditions, comprising a cholinergic drug which either activates acetyl choline receptors or inhibits the degradation of acetyl choline.
PCT/GB1997/002349 1996-09-03 1997-09-01 Use of cholinergic drugs Ceased WO1998009623A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40270/97A AU4027097A (en) 1996-09-03 1997-09-01 Method of treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9618341.3 1996-09-03
GBGB9618341.3A GB9618341D0 (en) 1996-09-03 1996-09-03 Method of treatment

Publications (2)

Publication Number Publication Date
WO1998009623A2 WO1998009623A2 (en) 1998-03-12
WO1998009623A3 true WO1998009623A3 (en) 1998-08-27

Family

ID=10799318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002349 Ceased WO1998009623A2 (en) 1996-09-03 1997-09-01 Use of cholinergic drugs

Country Status (4)

Country Link
AU (1) AU4027097A (en)
GB (1) GB9618341D0 (en)
WO (1) WO1998009623A2 (en)
ZA (1) ZA977867B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE541565T1 (en) 1999-05-27 2012-02-15 Khoury George F El TOPICAL USE OF MUSCARINIC AND OPIOID AGENTS FOR THE TREATMENT OF TINNITUS
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
EP1190709A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of tinnitus
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
PT2498771E (en) * 2009-11-12 2014-01-30 Acacia Pharma Ltd Use of bethanechol for treatment of xerostomia
GB201107533D0 (en) * 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857534A (en) * 1984-04-05 1989-08-15 North Carolina State University Method of maintaining ruminants on high energy low fiber diet
WO1994001108A1 (en) * 1992-07-02 1994-01-20 Theratech, Inc. Controlled release pilocarpine delivery system
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology
EP0689836A1 (en) * 1994-06-27 1996-01-03 Snow Brand Milk Products Co., Ltd. Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857534A (en) * 1984-04-05 1989-08-15 North Carolina State University Method of maintaining ruminants on high energy low fiber diet
WO1994001108A1 (en) * 1992-07-02 1994-01-20 Theratech, Inc. Controlled release pilocarpine delivery system
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology
EP0689836A1 (en) * 1994-06-27 1996-01-03 Snow Brand Milk Products Co., Ltd. Spirooxathiolane-quinuclidine derivative for the treatment of xerostomia

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
"Dordland's illustrated medical dictionary", 1985, SAUNDERS, PHILADELPHIA, XP002048998 *
ANONYMOUS: "Bethanechol chloride therapy for the anticholinergic effects of tricyclic antidepressants", INT. DRUG THER. NEWSLETT., vol. 11, June 1976 (1976-06-01), pages 21, XP002065304 *
AWAD: "Dysfunction of the detrusor and urethra in multiple sclerosis: the role of drug therapy", CAN. J. SURG., vol. 25, no. 3, July 1982 (1982-07-01), pages 259 - 262, XP002065301 *
BESINGER: "Multiple Sklerose", DTSCH APOTH. ZTG, vol. 21, no. 5, 1981, pages 218 - 221, XP002065298 *
CHEMICAL ABSTRACTS, vol. 110, no. 3, 16 January 1989, Columbus, Ohio, US; abstract no. 18433t, page 51; column 18438; XP002049000 *
DAMANSKI: "The neurogenic bladder of non-traumatic origin", PARAPLEGIA, vol. 6, no. 3, November 1968 (1968-11-01), pages 150 - 157, XP002065306 *
DE BUCK: "Les effets secondaires des médicaments psychotropes sur le tube digestif", REV. FR. GASTRO-ENTEROL., vol. 179, 1982, pages 27 - 32, XP002048988 *
EVERETT: "The use of bethanechol chloride with tricyclic antidepressants", AM. J. PSYCHIATRY, vol. 132, no. 11, 1975, pages 1202 - 1204, XP002048992 *
GARNIER M. ET DELAMARE V.: "Dictionaire des termes techniques de médecine", 1980, MALOINE S.A. ED., PARIS, XP002048999 *
GOODMAN AND GILLMAN' S , 7TH ED.: "pharmacological basis of therapeutics", 1987, MCMILLAN PUBLISHING COMPANY, NEW YORK , US, XP002048997 *
GOODMAN-GILLMAN: "Pharmacological basis of therapeutics", 1987, MACMILLAN PUBLISHING COMPANY, 7TH ED., NEW YORK, XP002065308 *
GOODMAN-GILLMAN: "Pharmacological basis of therapeutics", 1987, MACMILLAN PUBLISHING COMPANY, 7TH ED., NEW YORK, XP002065309 *
IWABUCHI: "A comparative study on the effects of four choline esters on the secretion of fluid and glycoprotein from rat submandibular glands", JPN J. PHARMACOL., vol. 48, no. 2, 1988, pages 175 - 184, XP002048995 *
JOENSUU: "Pilocarpine and carbacholine in the treatment of radiation-induced xerostomia", RADIOTHER. ONCOL., vol. 26, no. 1, 1993, pages 33 - 37, XP002048996 *
KHURANA: "Shy-Drager syndrome: diagnosis and treatment of cholinergic dysfunction", NEUROLOGY, vol. 30, no. 8, 1980, pages 805 - 809, XP002048994 *
KRSTIC ET AL.: "Salivation: differences in the action of nicotine and dimethylphenylpiperazinium in the cat", PERIOD. BIOL., vol. 90, no. 2, 1988, pages 281 - 283 *
LANGTON: "Multiple sclerosis- management and rehabilitation", INT. REHABIL. MED., vol. 2, no. 3, 1980, pages 116 - 125, XP002065299 *
MCGUIRE: "Urodynamic findings and long-term outcome management of patients with multiple sclerosis-induced lower urinary tract dysfunction", J. UROL., vol. 132, no. 4, 1994, pages 713 - 715, XP002065302 *
MERRIL ET AL.: "Vesical dysfunction induced by the major tranquilizers", J. UROL., vol. 107, May 1972 (1972-05-01), pages 769 - 771, XP002065294 *
PAKES: "Complication oc bethanechol use with antidepressants", DRUG INTELL. CLIN. PHARM., vol. 12, November 1978 (1978-11-01), pages 684, XP002065303 *
REMICK: "Clinical aspects of xerostomia", J. CLIN. PSYCHIATRY, vol. 44, no. 2, 1983, pages 63 - 65, XP002048990 *
ROSEN: "Nortriptyline in the hospitalized elderly : tolerance and side effect reduction", PSYCHOPHARMACOL. BULL., vol. 29, no. 2, 1993, pages 327 - 331, XP002048991 *
ROSEN: "Treatment of nortriptyline's side effects in elderly patients: a double-blind study of bethanechol", AM. J. PSYCHIATRY, vol. 150, no. 8, August 1993 (1993-08-01), pages 1249 - 1251, XP002048989 *
SCHOENENBERG: "Management of vesical dysfunction in multiple sclerosis", UROLOGY, vol. 16, no. 4, October 1980 (1980-10-01), pages 444 - 447, XP002065300 *
SCHUBERT: "Use of bethanechol with phenothiazines : a case report", AM. J. PSYCHIATRY, vol. 136, no. 1, 1979, pages 110 - 111, XP002048993 *
SEIDEL: "Multiple Sklerose : Symptomatische Therapie un rehabilitation", TW NEUROL. PSYCHIATRY, vol. 9, no. 10, 1995, pages 574 - 582, XP002065297 *
TOURTELOTTE: "Therapeutics of multiple sclerosis", CLIN. NEUROPHARMACOLOGY, vol. 2, no. CHAP.9, 1977, pages 179 - 199, XP002065296 *
WEIN: "Receptor function and drug action in the lower urinary tract", SEMIN. NEUROL., vol. 8, no. 2, 1988, pages 121 - 130, XP002065307 *
WOGGON: "Phamakotherapie der Depression", THERAPIEWOCHE, vol. 37, no. 11, 1987, pages 933 - 940, XP002065305 *
WOLTERS: "Medikamentöse Behandlung von funktionellen Blasenentleerungsstörungen", DTSCH ARZTEBL., vol. 77, no. 34, 1980, pages 2019 - 1038, XP002065295 *

Also Published As

Publication number Publication date
ZA977867B (en) 1998-05-27
GB9618341D0 (en) 1996-10-16
WO1998009623A2 (en) 1998-03-12
AU4027097A (en) 1998-03-26

Similar Documents

Publication Publication Date Title
ID21259A (en) DRUG DISTRIBUTION SYSTEMS FOR TWO OR MORE ACTIVE INGREDIENTS
ES2128761T3 (en) FORMULATION OF TIRILAZAD WITH COSOLVENTE FOR PARENTERAL ADMINISTRATION.
CO4290346A1 (en) Azithromycin Controlled Release Dosage Forms
MA26456A1 (en) PHARMACEUTICAL FORMULATIONS FOR THE EXTENDED DELIVERY OF MEDICAMENT.
FI955091L (en) Improved pharmaceutically acceptable mixtures containing alcohol and hydrophobic drug
KR970702705A (en) MEDICAL LINEAR ACTUATOR FOR SURGICAL DELIVERY.MANUIPULATION.AND EXTRACTION
EP0707471A4 (en) NEW DRUG DELIVERY SYSTEMS
AU4989997A (en) Soluble form osmotic dose delivery system
WO1995017156A3 (en) Ethanol substitutes
EP0995434A3 (en) Medicinal aerosol formulations
CA2102630A1 (en) Pharmaceutical compositions of compacted medicaments
BR9607851B1 (en) combination and pharmaceutical formulation.
EE05506B1 (en) Drug delivery device, especially for administration of progestins and strogens
ATE232100T1 (en) OMEPRAZOLE MICROGRANULES PROTECTED AGAINST STOMACH JUICE, PRODUCTION PROCESS AND PHARMACEUTICAL PREPARATIONS
AR008886A1 (en) USE OF AN H +, K + -ATPASE INHIBITOR IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NASAL POLIPS, OF THE WIDAL SYNDROME, USE OF SUCH INHIBITOR AND A GLUCOCORTICOID FOR THE MANUFACTURE OF A PHARMACEUTICAL FORMULATION AND PHARMACEUTICAL FORMULATION
WO1998009623A3 (en) Use of cholinergic drugs
NO990440L (en) Preparation that includes mupirocin and chlorhexidine
FI955730A7 (en) Drug delivery system for alpha-adrenoreceptor blocking agents
WO1999021574A3 (en) Enhancement of morphogen activity
TW366284B (en) Pharmaceutical antitussive composition of delta-receptor antagonist
WO1995018600A1 (en) Dermatological composition based on crotamiton and at least one cationic antiseptic
DE69934902D1 (en) MEDICAMENT AGAINST DRUG DEPENDENCE
AU1314899A (en) Emulsions for aerosolization and drug delivery
ES2184121T3 (en) FORMULATION FOR THE TREATMENT AND / OR PROFILAXIS OF DEMENTIA.
AU2502301A (en) Medicament and combination of compatible medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998512338

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase